<DOC>
	<DOCNO>NCT01406327</DOCNO>
	<brief_summary>The objective post-marketing surveillance study evaluate incidence adverse event Japanese subject pulmonary arterial hypertension treat ambrisentan basd prescribe information condition general clinical practice also grasp follow item ; 1 . Unknown adverse drug reaction ( ADRs ) 2 . Incidence ADRs medical product actual clinical practice 3 . Factors influence safety ambrisentan 4 . Factors influence efficacy ambrisentan 5 . Prognosis subject well efficacy safety ambrisentan long-term use ( VOLIBRIS® trademark Gilead Sciences , Inc , . GSK use license . )</brief_summary>
	<brief_title>Drug Use Investigation VOLIBRIS® ( Ambrisentan ) ( Pulmonary Arterial Hypertension )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Must use ambrisentan first time Subjects hypersensitivity ambrisentan Subjects pregnant might pregnant Subjects severe hepatic disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>